Plasma Cell Dyscrasia
9
2
2
4
Key Insights
Highlights
Success Rate
80% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 59/100
11.1%
1 terminated out of 9 trials
80.0%
-6.5% vs benchmark
0%
0 trials in Phase 3/4
50%
2 of 4 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 4 completed trials
Clinical Trials (9)
Integrated Cancer Repository for Cancer Research
Pilot Trial of Homebound Stem Cell Transplantation
Plerixafor Harvesting And No Chemotherapy for Transplantation of Autologous STem Cells In Cancer (PHANTASTIC)
Autologous Stem Cell Transplantation for Patients With AL Amyloidosis
Companion for CAR-T Web App During Chimeric Antigen Receptor T-cell Therapy
Shorter Course Tacro After NMA, Related Donor PBSCT With High-dose Posttransplant Cy for Hard-to-Engraft Malignancies
A Diagnostic Screening Trial Seeking AL Amyloidosis Very Early
Stem Cell Transplant for Patients With Blood Malignancy Using Donors and Less Toxic Chemotherapy With CAMPATH 1H
Reduced Intensity Preparative Regimen Followed by Stem Cell Transplant (FAB)